Étude de réponse histologique du cancer du sein HER2+ après chimiothérapie néoadjuvante associant taxane et trastuzumab

Conclusion Le taux de réponse histologique complète correspond à la moyenne basse internationale. L’importance des données manquantes n’a pas permis de dégager d’autre facteur pronostique qu’un Ki67>44 %. Objectives In our study, we aimed to assess the pathologic complete response after neo-additive chemotherapy that contains a taxan associated to trastuzumab for patients treated from breast cancer at the institute Jean-Godinot between 2012 and 2014, and to evaluate factors associated to this pathologic complete response. Methods Retrospective study with clinical, anatomopathologic and radiologic parameters analysis before and after new adjuvant chemotherapy. The statistical analysis was done on logiciel XL-STAT, the Mann-Whitney-Wilcoxon for quantitative variables and Fisher exact tests for qualitative variables, the Spearman rang test. Results The rate of pathologic complete response is 38.8%. The prognostic factor associated to pathologic complete response is a Ki-67>44%. Conclusion The pathologic complete response rate corresponds to international lower rate; because of the lack of several data, we found out only one prognostic factor, Ki-67>44%.
Source: Gynecologie Obstetrique and Fertilite - Category: OBGYN Source Type: research